Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Saturday.
Several other research analysts also recently issued reports on the company. Zacks Investment Research upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, September 17th. Cantor Fitzgerald set a $50.00 price objective on Aclaris Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Aclaris Therapeutics has a consensus rating of “Hold” and a consensus price target of $43.50.
Shares of Aclaris Therapeutics stock opened at $13.58 on Friday. Aclaris Therapeutics has a 1 year low of $12.84 and a 1 year high of $27.20. The company has a market cap of $449.84 million, a P/E ratio of -5.43 and a beta of 1.22.
Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Friday, August 3rd. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.05) by $0.04. Aclaris Therapeutics had a negative return on equity of 49.45% and a negative net margin of 1,584.99%. The firm had revenue of $3.68 million during the quarter, compared to the consensus estimate of $2.76 million. Analysts predict that Aclaris Therapeutics will post -4.6 earnings per share for the current fiscal year.
In other Aclaris Therapeutics news, Director Stephen A. Tullman purchased 6,250 shares of the business’s stock in a transaction on Wednesday, August 15th. The stock was bought at an average cost of $15.97 per share, for a total transaction of $99,812.50. Following the acquisition, the director now owns 163,757 shares of the company’s stock, valued at approximately $2,615,199.29. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stephen A. Tullman purchased 7,100 shares of the business’s stock in a transaction on Thursday, October 4th. The stock was acquired at an average price of $14.00 per share, with a total value of $99,400.00. Following the completion of the acquisition, the director now directly owns 177,457 shares in the company, valued at approximately $2,484,398. The disclosure for this purchase can be found here. Insiders acquired a total of 19,950 shares of company stock valued at $298,213 over the last quarter. 17.00% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC raised its holdings in Aclaris Therapeutics by 31.1% in the 2nd quarter. FMR LLC now owns 3,355,785 shares of the biotechnology company’s stock valued at $67,015,000 after acquiring an additional 796,805 shares during the last quarter. BlackRock Inc. raised its holdings in Aclaris Therapeutics by 9.7% in the 2nd quarter. BlackRock Inc. now owns 2,311,641 shares of the biotechnology company’s stock valued at $46,163,000 after acquiring an additional 204,215 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Aclaris Therapeutics by 8.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 423,001 shares of the biotechnology company’s stock valued at $8,447,000 after acquiring an additional 31,339 shares during the last quarter. Rice Hall James & Associates LLC raised its holdings in Aclaris Therapeutics by 88.5% in the 2nd quarter. Rice Hall James & Associates LLC now owns 399,342 shares of the biotechnology company’s stock valued at $7,975,000 after acquiring an additional 187,545 shares during the last quarter. Finally, Highbridge Capital Management LLC raised its holdings in Aclaris Therapeutics by 50.0% in the 1st quarter. Highbridge Capital Management LLC now owns 300,000 shares of the biotechnology company’s stock valued at $5,256,000 after acquiring an additional 100,000 shares during the last quarter. Institutional investors own 99.75% of the company’s stock.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Further Reading: Hedge Funds – How They Work For Investors
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.